HK Stock MarketDetailed Quotes
02157 LEPU BIO-B
- 2.680
- +0.110+4.28%
Market Closed Dec 11 16:08 CST
4.58BMarket Cap-57.02P/E (TTM)
2.710High2.550Low3.71MVolume2.570Open2.570Pre Close9.72MTurnover0.22%Turnover RatioLossP/E (Static)1.71BShares6.50052wk High4.57P/B4.44BFloat Cap2.16052wk Low--Dividend TTM1.66BShs Float31.800Historical High--Dividend LFY6.23%Amplitude2.160Historical Low2.617Avg Price1000Lot Size--Div YieldTTM--Div Yield LFY
About LEPU BIO-B Company
Lepu Biotechnology Co., Ltd. is an innovative biopharmaceutical company based in China and focusing on the field of cancer treatment for the world. We have developed a strong product pipeline focusing on oncology drug candidates, including clinical and pre-clinical ADCs, oncolytic virus drugs, and immunotherapy. We plan to commercialize the product pipeline domestically by building a professional sales and marketing team, and promote the product pipeline to overseas markets such as the US and Europe through cooperation with overseas companies.
Company Profile
Symbol02157
Company NameLEPU BIO-B
ISINCNE100004SM4
Listing DateFeb 23, 2022
Issue Price7.13
Shares Offered126.88M share(s)
FoundedJan 19, 2018
Registered AddressChina
Chairmanzhongjie pu
Secretaryshaojuanliyunyi li
Company CategoryOther
Registered Office2nd Floor, Building 41, No. 518 Xinzhuan Road, Songjiang District, Shanghai, China
Head Office and Principal Place of Business5th Floor, Manulife Plaza, 348 Kwun Tong Road, Kowloon, Hong Kong
Fiscal Year Ends12-31
Employees491
MarketHong Kong motherboard
Phone(021)67696099
Websitehttp://www.lepubiopharma.com
Business Lepu Biotechnology Co., Ltd. is a Chinese biopharmaceutical company focusing on the field of cancer treatment. The company mainly develops product lines for cancer drug candidates, including clinical and pre-clinical ADCs, oncolytic virus drugs, and immunotherapy. The company's main pipeline assets include MRG003, MRG002, HX008 and LP002, and three key clinical stage drug candidates. The company's products are sold to domestic and overseas markets.
Company Executives
- Name
- Position
- Salary
- zhongjie pu
- Chairman, Executive Director, Chairman of the Strategy Committee, Member of the Remuneration and Evaluation Committee, Nomination Committee Members, Authorized Representative
- --
- ziye sui
- Executive Director, General Manager, Strategy Committee Members
- --
- jue pu
- Non-executive Directors, Audit Committee Members
- --
- hongbing yang
- Non-executive Directors
- --
- demin zhou
- Independent Non-Executive Director, Chairman of the Nomination Committee, Strategy Committee Members
- --
- haifeng yang
- Independent Non-Executive Director, Chairman of the Remuneration and Evaluation Committee, Audit Committee Members, Nomination Committee Members
- --
- fengmao hua
- Independent Non-Executive Director, Chairman of the Audit Committee, Member of the Remuneration and Evaluation Committee
- --
- yang xu
- Auditors
- --
- lixuan zhao
- Employee Representative Supervisor
- --
- ming yang
- Auditors
- --
- minmin qin
- Chief Technology Officer
- --
- lei fang
- VP
- --
- yunyi li
- Chief Financial Officer, Joint Company Secretary, Board Secretary
- --
- shaojuan li
- Joint Company Secretary, Authorized Representative
- --
Heat List
HK
Overall
Symbol
Price
% Chg
No Data
